News

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release…

2 years ago

Univec Appoints Lauren Herron Vice President

BALTIMORE, MD / ACCESSWIRE / May 2, 2022 / Univec, Inc. (OTCMarktets:UNVC) a mental health and substance abuse total wraparound…

2 years ago

Cloud DX Reports Fiscal 2021 Annual Results

KITCHENER, ON / ACCESSWIRE / May 2, 2022 / Cloud DX (TSXV:CDX) (OTCQB:CDXFF), (the "Company") a leading North American provider…

2 years ago

Mental Health Awareness Month: Expert on Grief, Trauma and Burnout

Need an expert commentator on grief, trauma and burnout?Meet Sherry Walling, MAT, PhDMINNEAPOLIS, MN / ACCESSWIRE / May 2, 2022…

2 years ago

Hospice of Westchester Announces New Officers and Members of the Board of Directors

WHITE PLAINS, NY / ACCESSWIRE / May 2, 2022 / Hospice of Westchester (HOW) has voted in new officers and…

2 years ago

Novamind Announces Virtual Group Health Coaching

Collaboration with HealCommunity Offers Remote Access to Reimbursable Group Therapy OptionTORONTO, ON / ACCESSWIRE / May 2, 2022 / Novamind…

2 years ago

Planet 13 Expands Popular TRENDI Brand to California with Premium Flower

LAS VEGAS, NV / ACCESSWIRE / May 2, 2022 / Planet 13 Holdings Inc. (CSE:PLTH)(OTCQX:PLNHF) ("Planet 13" or the "Company"),a…

2 years ago

Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer

– Experienced oncology drug developer with more than two decades advancing treatments for solid tumors and hematologic malignancies joins Codiak leadership…

2 years ago

F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company…

2 years ago

Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD™ IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern

The Phase I safety and pharmacokinetic study in 24 healthy volunteers has completed enrollment. The study is still blinded, but…

2 years ago